ArticleInternational breastfeeding journal2026
Safety of tacrolimus during lactation: an exploratory retrospective analysis in a small Japanese cohort.
Article in International breastfeeding journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTacrolimus is a calcineurin inhibitor immunosuppressant widely used in organ transplantation and the management of autoimmune diseases. Tacrolimus is generally considered to be safe for women who are breastfeeding; however, pharmacokinetic differences related to genetic background have been reported, and clinical data focusing on Japanese women during lactation remain scarce. As such, this study evaluated the safety of tacrolimus in Japanese women diagnosed with autoimmune diseases during breastfeeding.
methodsThis exploratory retrospective analysis was conducted at a single tertiary care hospital in Japan. Participants were divided into 2 groups: breastfeeding mothers prescribed tacrolimus (n = 6); and breastfeeding mothers who did not receive tacrolimus (control group; n = 12). Most infants were primarily breastfed. Between January 2011 and June 2018, maternal characteristics and adverse events in infants from birth to the 1-month checkup were collected from medical records and “plan-sheets for lactation” completed at approximately 28 weeks’ gestation.
resultsAll mothers in the tacrolimus group received a daily tacrolimus dose of 3 mg throughout the observation period. The adverse events observed in the tacrolimus group included jaundice (n = 5), rashes (n = 3), vomiting (n = 3), head hematoma (n = 2), minor skin lesion (n = 1), and respiratory failure (n = 1). All adverse events were non-serious and the infants recovered uneventfully. The Isobe Neonatal Withdrawal Syndrome score was 0 in all evaluated infants in the tacrolimus group during the first month after birth. All 6 mother-infant pairs in the tacrolimus group continued breastfeeding and maternal medication through the 1-month postpartum checkup. A significantly higher incidence of vomiting was observed in the tacrolimus group compared with the control group.
conclusionPreliminary observations in this small Japanese cohort revealed no serious adverse events in breastfed infants during the first month, but larger studies are required to confirm safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.